

## Afghanistan

### Support for Vaccine: Inactivated Polio Virus This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b>	Afghanistan						
<b>2. Vaccine grant number:</b>	15-AFG-08h-Y, 1518-AFG-25c-X, 19-AFG-25c-X, 20-AFG-25c-X						
<b>3. Date of Decision Letter:</b>	30-Sep-19						
<b>4. Date of the Partnership Framework Agreement:</b>	30-Apr-13						
<b>5. Programme title:</b>	New Vaccine Support (NVS), Inactivated Polio Virus, Routine						
<b>6. Vaccine type:</b>	Inactivated Polio Virus						
<b>7. Requested product presentation and formulation of vaccine:</b>	Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID						
<b>8. Programme Duration:<sup>1</sup></b>	2015-2020						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2015-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>
Programme Budget (US\$)	7,929,401	3,167,500	-	-	-	-	11,096,901
<b>10. Vaccine introduction grant</b>							
	<b>Approval</b>						
	<b>Year</b>	<b>Grant Number</b>					<b>Amount (US\$)</b>
	2015	15-AFG-08h-Y					823,000
	<b>Disbursement</b>						
	<b>Disbursement date</b>			<b>Amount (US\$)</b>			
	28 April, 2015			823,000			
<b>11. Product switch grant</b>	<b>Not applicable</b>						

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

<b>12. Indicative Annual Amounts:<sup>3</sup></b>		(subject to the terms of the Partnership Framework Agreement, if applicable)	
<b>Type of supplies to be purchased with Gavi funds</b>	<b>2015-2019</b>	<b>2020</b>	<b>2021</b>
Number of vaccine doses		1,426,700	-
Annual Amounts (US\$)	7,929,401	3,167,500	-
<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
<b>14. Self-procurement:</b>	Not applicable		
<b>15. Co-financing obligations:</b>	<p style="text-align: center;"><b>Not applicable</b></p> <p>Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.</p>		
<b>16. Operational support for campaigns:</b>	<b>Not applicable</b>		
<b>17. Additional Reporting Requirements:</b>			
		Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:			
<ul style="list-style-type: none"> <li>• vaccine stock levels including buffer stock, by end of March;</li> <li>• number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>• Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>		31 March 2020	15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.		To be agreed with Gavi Secretariat	

**18. Financial clarifications:**

Country shall provide the following clarifications to Gavi\*:

Not applicable

\* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

**19. Other conditions:**

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

**On behalf of Gavi**



Thabani Maphosa  
Managing Director, Country Programmes  
30 September 2019